Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
ISTH Academy Webinar: Human Platelet Generation in Vitro
Tell a Friend About This EventTell a Friend
ISTH Academy Webinar: Human Platelet Generation in Vitro

When: Tuesday, February 7, 2017
23:00 GMT/UTC

« Go to Upcoming Event List  


Human Platelet Generation in Vitro

ISTH Core Curriculum 26.5, 26.6 – Transfusion

February 7, 2017 23:00 - 24:00 UTC

(February 7 at 18:00 Eastern US; February 8 at 8:00 Japan)


Koji Eto "iPS cell-derived Megakaryocytes"
To supply transfusion products of 200-300 billion platelets derived from human induced pluripotent stem (iPS) cells ex vivo, the manipulation of megakaryopoiesis and platelet shedding must be considered. Dr. Eto will introduce an overview of an in vitro differentiation method for megakaryocytes and discuss how to increase the cell number from our cryopreserved self-renewing megakaryocyte cell line, immortalized megakaryocyte cell line (imMKCL), which was established from human iPS cells.

Peter Newman "'Designer' Platelets"
Dr. Newman will discuss the use of CRISPR/Cas9 technology to modify the genome of human induced pluripotent stem (iPS) cells prior to their differentiation into megakaryocytes and platelets so that patient-matched Designer Platelets can be generated. Platelets and their hematopoietic progenitor cells expressing specific, low-frequency platelet alloantigens may be of immediate use for research and for clinical diagnostic typing, and for future therapeutic use once the technology for producing large numbers of in vitro-derived platelets matures.

Moderator: Jonathan Thon





Koji Eto
Koji Eto, MD, PhD is Deputy Director of the Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan and cross-appointed Professor of the Graduate School of Medicine, Chiba University, Japan. His laboratory at CiRA (Kyoto campus) focuses on the generation of platelets and erythrocytes in vitro from human iPS cells toward clinical application. Research includes how epigenetic modifications and the microenvironment regulate the self-renewal of hematopoietic stem cell-derived progenitors including megakaryocyte progenitor cells, and control of intact platelet shedding, from megakaryocytes with the greater aim of efficiently.

He was trained as a physician of cardiovascular medicine in Tokyo and worked at Professor Sanford Shattil at The Scripps Research Institute, La Jolla, California, where he studied integrin signaling in platelets and megakaryocytes from 2000 to 2003. And then he studied human embryonic stem cell or iPS cell-derived in vitro differentiation system as Assistant and Associate Professor at The University Tokyo from 2004 to 2011.

Peter Newman
Peter J. Newman is Vice President for Research at BloodCenter of Wisconsin and Associate Director of its Blood Research Institute. Dr. Newman’s major research accomplishments include elucidation of the molecular basis of the major human platelet alloantigen systems, including the PlA1/PlA2 polymorphism, the discovery of PECAM-1, and numerous contributions to the understanding of the role of activating and inhibitory receptors that control platelet activation. Dr. Newman has published more than 175 original research articles, book chapters and reviews on the subject of platelet and endothelial cell biology, cell adhesion, and signal transduction. Current research activities include the structural biology of PECAM-1, the role of PECAM-1 in endothelial cell junctional integrity, and novel applications of CRISPR/Cas9 gene editing technology to modify platelet- and megakaryocyte-specific alloantigens in induced pluripotent stem (iPS) cells. Dr. Newman has served on the Executive Committee of the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Council of the AHA, chaired its Annual Meeting in 2004 and served on its Council from 2010-2012. He chaired the Hemostasis Gordon Conference in 2008, has been on the editorial board of Blood, and currently serves the AHA as an Associate Editor of the journal ATVB. He received an Investigator Recognition Medal from the International Society of Thrombosis (ISTH) in 1997, a Special Recognition Award from the ATVB Council of the AHA in 2001, the Emil von Behring Award from the German Society for Transfusion Medicine in 2007, and a Distinguished Career Award from the ISTH in 2013.

Jonathan Thon, PhD, CEO, Chief Scientific Officer, Co-Founder 
Dr. Thon is an Assistant Professor at Brigham and Women’s Hospital and Harvard Medical School where his research is focused on developing bio-mimetic microfluidic platforms to generate functional platelets and new targeted therapies for thrombocytopenia. By combining novel concepts in bone marrow physiology with cutting-edge technical advances in tissue engineering Dr. Thon’s lab is developing safer and scalable alternatives to donor-dependent human platelet transfusions for hematological diseases and trauma. Dr. Thon began this research as a Ph.D. candidate in the lab of Dr. Dana Devine at the University of British Columbia, Canada, where he worked closely with Canadian Blood Services for the improvement of the processing and storage of blood platelets and the identification of mechanisms regulating their storage-related deterioration. Dr. Thon’s postdoctoral research was continued in Dr. Joseph Italiano’s lab at Brigham and Women’s Hospital and Harvard Medical School in Boston, where he studied the cytoskeletal mechanics and signaling pathways regulating platelet formation, leading to the identification of intermediate stages and triggers of platelet production. This work led to the development of a biomimetic human platelet bioreactor and surrounding intellectual property, with which he founded Platelet BioGenesis Inc.

Click here to register

Membership Management Software Powered by YourMembership  ::  Legal